Bluesky Facebook Reddit Email

SARS-CoV-2 antibody response to 2 or 3 doses of BioNTech-Pfizer vaccine in patients with cancer

01.07.22 | JAMA Network

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

What The Study Did: This study assessed the antibody response to two or three doses of the BioNTech-Pfizer SARS-CoV-2 vaccine in 163 patients treated with anticancer agents for solid tumors.

Authors: Charlotte Fenioux, M.D., of Hôpital Henri Mondor in Créteil, France, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamaoncol.2021.7777)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2021.7777?guestAccessKey=64f57de0-65f5-4ccc-9c30-3abe123b5e3b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=010722

JAMA Oncology

Keywords

Article Information

Contact Information

JAMA Network Media Relations
JAMA Network
mediarelations@jamanetwork.org

How to Cite This Article

APA:
JAMA Network. (2022, January 7). SARS-CoV-2 antibody response to 2 or 3 doses of BioNTech-Pfizer vaccine in patients with cancer. Brightsurf News. https://www.brightsurf.com/news/1WRR6W2L/sars-cov-2-antibody-response-to-2-or-3-doses-of-biontech-pfizer-vaccine-in-patients-with-cancer.html
MLA:
"SARS-CoV-2 antibody response to 2 or 3 doses of BioNTech-Pfizer vaccine in patients with cancer." Brightsurf News, Jan. 7 2022, https://www.brightsurf.com/news/1WRR6W2L/sars-cov-2-antibody-response-to-2-or-3-doses-of-biontech-pfizer-vaccine-in-patients-with-cancer.html.